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It is well documented that high therapeutic doses of oxazaphosphorines, cyclophosphamide (CP) and ifosfamide (IFO), are asso-
ciated with cardiomyopathy. This study investigated whether oxazaphosphorines alter the expression of organic cation/carnitine
transporter (OCTN2) and antioxidant genes and if so, whether these alterations contribute to CP and IFO-induced cardiotoxicity.
Adult male Wistar albino rats were assigned to one of six treatment groups namely, control, L carnitine, CP, IFO, CP plus
L carnitine and IFO plus L carnitine. In cardiac and kidney tissues, CP and IFO signiﬁcantly decreased mRNA and protein
expression of OCTN2. Oxazaphosphorines signiﬁcantly increased serum acyl-carnitine/free carnitine ratio and urinary carnitine
excretionandsigniﬁcantlydecreasedtotalcarnitineincardiactissues.Interestingly,carnitinesupplementationcompletelyreversed
the biochemical and gene expression changes-induced by oxazaphosphorines to the control values, except OCTN2 expression
remained inhibited by IFO. Data from this study suggest that: (1) Oxazaphosphorines decreased myocardial carnitine content
following the inhibition of OCTN2 mRNA and protein expression in cardiac tissues. (2) Oxazaphosphorine therapy increased
urinary loss of carnitine secondary to the inhibition of OCTN2 mRNA and protein expression in proximal tubules of the kidney.
(3) Carnitine supplementation attenuates CP but not IFO-induced inhibition of OCTN2 mRNA and protein expression in heart
and kidney tissues.
1.Introduction
Even today, 53 years after its introduction, the nitrogen
mustard alkylating oxazaphosphorine prodrug cyclophos-
phamide (CP) and its structural isomer ifosfamide (IFO)
are the most widely used in polychemotherapy regimens
and immunosuppressive protocols [1, 2]. Several clinical
and experimental studies reported that administration of
high therapeutic doses of CP can cause lethal cardiotoxicity
during or soon after (10 days) administration [3–8]. It is
manifested clinically as acute or subacute onset of congestive
heart failure, arrhythmias, cardiac tamponade, and myocar-
dial depression [3, 9, 10]. The incidence of CP-induced car-
diotoxicity was reported in several clinical studies to be 20–
25% with 8–12% mortality [10–12]. However, it seems that
low doses of CP can be eﬀective with little toxicity [13].
Although IFO has not been added to the list of antineoplastic
therapies associated with major cardiac complications, its
cardiotoxicity wasreported asisolated clinicalcasesin cancer
patients receiving IFO in combination with other anticancer
drugs [14]. Cardiac eﬀects reported with IFO therapy
include supraventricular arrhythmias with a 30% incidence2 Oxidative Medicine and Cellular Longevity
of congestive heart failure and dilated cardiomyopathy in
patients receiving 16–18g/m2 of IFO [14, 15]. Earlier and
recent studies reported that high doses of CP and IFO
induced hemorrhagic myocardial necrosis and increased
lactate dehydrogenase and creatine phosphokinase activities
[16–18]. Recent study in our laboratory have demonstrated
that IFO is usually associated in the setting of nephrotoxicity
and increased urinary carnitine loss, with severe cardiotox-
icity [19]. The pathogenesis of oxazaphosphorines-induced
acutecardiotoxicitywasattributedprimarilytoanincreasein
oxygen-free radicals and decrease in the antioxidant defense
mechanism in the myocardium [4, 17–19].
L carnitine (β-hydroxy-γ-trimethyl-amino-butyric acid)
is an essential cofactor for the transport of long-chain fatty
acids from cytoplasmic compartment into mitochondria,
where β-oxidation enzymes are located [20, 21]. Humans
cover their carnitine needs from endogenous synthesis, in
liver, kidney, brain and testis, and exogenous dietary sources
mainlyredmeatanddairyproducts[20,22].Inrats,theﬁnal
enzyme in carnitine biosynthetic pathway, γ-butyrobetaine
hydroxylase, is found primarily in liver [20, 22]. The
eﬀect of L carnitine on long-chain fatty acid oxidation in
the heart depends on its intracellular concentration which
itself dependent on the activity of organic cation/carnitine
transporter (OCTN2). Organic cation/carnitine transporter
is sodium-dependent and high-aﬃnity carnitine transporter
which mediates carnitine transport across the plasma mem-
brane into the cells and serves to maintain carnitine levels
in serum by functioning as a reabsorption transporter of
carnitine in proximal tubules after glomerular ﬁltration
[20, 23, 24] .S e v e r a ls t u d i e sr e p o r t e dt h a tC Pa n dI F O
therapy is associated with increased secretion of carnitine
derivativesintheurinewithsubsequentsecondarydeﬁciency
of the molecule [8, 19, 25–29]. Visarius et al. reported that
chloroacetaldehyde (CAA) and thiodiglycolic acid (TDGA),
the two major toxic metabolites of oxazaphosphorines,
inhibit the oxidation of long-chain fatty acids (carnitine
dependent) but not medium chain-fatty acids (carni-
tine independent) indicating that these compounds either
sequester carnitine or inhibit carnitine palmitoyl transferase
system [25, 27]. Marthaler et al. was the ﬁrst to report that
IFO therapy is associated with 10-fold increase in urinary
carnitine excretion [26]. Using an animal model of carnitine
deﬁciency, recent studies in our laboratory reported, for the
ﬁrst time, that both IFO and CP are associated with severe
cardiotoxicity secondary to the increase in urinary losses of
carnitine and the decrease in myocardial carnitine content,
intramitochondrial CoA-SH and ATP production [8, 19]. In
rat kidney tissues, carnitine deﬁciency and energy starvation
were reported to constitute risk factors and should be viewed
as a mechanism during CP-induced nephrotoxicity in rats
[29]. Recently, it has been demonstrated that carnitine
supplementation prevents the development of IFO-induced
Fanconi syndrome by increasing intracellular carnitine con-
tent and intramitochondrial CoA-SH, with the consequent
improvement in ATP production [30]. Recent in vitro study
by Ciarimboli et al. has demonstrated, for the ﬁrst time, that
IFO but not CP is a substrate for OCTN2, which provide a
cell-speciﬁc explanation for IFO-induced fanconi syndrome
and oﬀer a new potential target for selective protective
interventions in cancer treatment with oxazaphosphorines
[31]. Although we have previously reported that CP and IFO
induce its organ toxicity by altering carnitine and energy
status in mitochondria [8, 19, 30], no mechanism for these
eﬀects has been ascertained. Accordingly, the current study
has been initiated to investigate whether oxazaphosphorines
therapy alters the expression of OCTN2 gene in cardiac and
kidney tissues, and if so, whether these alterations contribute
to oxazaphosphorines-induced cardiotoxicity.
2.MaterialsandMethods
2.1. Materials. Endoxan and Holoxan vials (Baxter oncology
GmbH, Germany) were gifted from King Khalid University
Hospital drug store, King Saud University, Kingdom of Saudi
Arabia. Each Endoxan vial contains 500mg CP, whereas
each Holoxan vial contains 1g IFO in a dry lyophilized
powder form. The content of each vial was freshly dissolved
in sterile water for injection immediately before injection.
L carnitine was kindly supplied by Dr. Zaven Orfalian,
Sigma-Tau Pharmaceuticals, Pomezia, Italy. It has been
supplied as white powder in a noncommercial plastic bottles
contains 100g, and it was freshly dissolved in normal saline
prior to injection. Primers and probes were designed using
Primer Express 3.0 (Applied biosystem, USA) and purchased
from Metabion International AG (Germany). OCTN2 and
GAPDH monoclonal antibodies have been purchased from
Santa Cruz biotechnology, Inc. (Heidelberg, Germany). All
other chemicals used were of the highest analytical grade.
2.2. Animals. Adult male Wistar albino rats, weighing 180–
200g,wereobtainedfromtheAnimalCareCenter,Collegeof
Pharmacy, King Saud University, Riyadh, Kingdom of Saudi
Arabia and were housed in metabolic cages under controlled
environmental conditions (25◦C and a 12hlight/dark cycle).
Animalshadfreeaccesstopulverizedstandardratpelletfood
a n dt a pw a t e r .T h ep r o t o c o lo ft h i ss t u d yh a sb e e na p p r o v e d
by Research Ethics Committee of College of Pharmacy, King
Saud University, Riyadh, Kingdom of Saudi Arabia.
2.3. Experimental Design. To achieve the ultimate goals of
this study, a total of 60 adult male Wistar albino rats were
used and divided at random into 6 groups of 10 animals
each. Rats of group 1 (control group) were received I.P.
injection of normal saline (2.5mL/kg/day) for 10 successive
days. Animals in group 2 (carnitine-supplemented group)
were given L carnitine (200mg/kg/day, I.P.) for 10 successive
days as previously described [30]. Animals in group 3 (CP
group) were received normal saline for 5 days before and
5 days after a single dose of CP (200mg/kg/I.P.) according
to previously published studies [4, 8, 17]. Rats of group 4
(IFOgroup)werereceivednormalsalinefor5successivedays
followed by IFO (50mg/kg/day, I.P.) for 5 successive days
according to Sayed-Ahmed et al. [19]. Rats of group 5 (CP-
carnitine supplemented rats) were given the same doses of
L carnitine as group 2 for 5 days before and 5 days after a
single dose of CP as group 3 according to Fatani et al. [8].Oxidative Medicine and Cellular Longevity 3
Rats of group 6 (IFO-carnitine supplemented rats) were
given the same doses of L carnitine as group 2 for 5 days
beforeand5daysconcomitantwithIFOasgroup4according
to Sayed-Ahmed [30]. Immediately after the last dose of
the treatment protocol, 24-hour urine was collected for
monitoring urinary carnitine excretion. Animals were then
sacriﬁced by decapitation after exposure to ether in a dessi-
cator kept in a well-functioning hood, and blood samples
were obtained. Serum was separated for measurement of
serumlactatedehydrogenase(LDH),creatinephosphokinase
iso-enzyme (CK-MB) and acyl-carnitine (AC)/free carnitine
(FC) ratio. Hearts were quickly excised for measurement of
total carnitine and mRNA expression of OCTN2, GPx, and
SOD genes. Kidneys were also isolated for quantiﬁcation
of mRNA expression of OCTN2 gene. Moreover, protein
expression of OCTN2 was measured in heart and kidney
tissues.
2.4. Methods
2.4.1. Quantiﬁcation of mRNA Expression by Real-Time
Polymerase Chain Reaction
Total RNA Extraction. Total RNA was extracted from heart
and kidney tissues by Trizol method according to the
standard protocol as previously described [32]. Brieﬂy, RNA
was extracted by homogenization (Polytron; Kinematica,
Lucerne,Switzerland)inTRIzolreagent(GibcoBRL)atmax-
imumspeedfor90–120s.Thehomogenatewasincubatedfor
5minatroomtemperature.A1:5volumeofchloroformwas
added,andthetubewasvortexesandsubjectedtocentrifuga-
tion at 12,000g for 15min. The aqueous phase was isolated,
and the total RNA was precipitated by absolute ethanol.
After centrifugation and washing the total RNA was ﬁnally
eluted in 20μL of diethyl pyrocarbonate-treated water. The
quantity was characterized using a UV spectrophotometer
(NanoDrop 8000, Thermo Scientiﬁc, USA). The isolated
RNA has a 260/280 ratio of 1.9–2.1.
First-Strand cDNA Synthesis Using SuperScript II RT. First-
strand cDNA was synthesized from 1μgo ft o t a lR N A
by reverse transcription with a SuperScript ﬁrst-strand
synthesis system kit (Invitrogen, CA, USA), according to the
manufacturer’s instructions.
Real Time PCR. Real-time reaction was performed using the
KAPA PROBE FAST qPCR kit master mix (KAPA Biosysems,
USA) and the 2−ΔΔCt method. GAPDH gene was used as the
endogenouscontrol.PCRassaywasoptimizedbyvaryingthe
PCR conditions such as the concentration of cDNA, primers
and probes, ampliﬁcation cycle number, and annealing
temperature. Brieﬂy, a standard 25μL reaction mixture has
contained in ﬁnal concentration of 1x KAPA PROBE FAST
qPCR master mix buﬀer, 0.4μMo fe a c hf o r w a r da n dr e v e r s e
primers, 0.2μM Probe for OCTN2, GPx, SOD and GAPDH
(Table 1), 100ng of cDNA and RNase, and DNase-free water.
The reaction was done in an ABI 96-well optical reaction
plate placed on ice before cDNA template was added. The
standard thermal cycling conditions of initial 50◦Cf o r2m i n
and 95◦C for 10min followed by 40 cycles at 95◦Cf o r1 5
second and 60◦C for 1min were used. All reactions were
performed using an ABI 7500 System (Applied Biosystem,
USA). Experiments were performed in triplets for all data
points. Each qPCR reaction included no-template controls.
2.4.2. Western Blot Analysis of OCTN2 Protein. For western
blot analysis, heart and kidney tissues were washed with ice-
cold PBS, and the protein extracts were prepared using ice-
cold cell lysis buﬀer supplemented with protease inhibitor
cocktail (IBI SCIENTIFIC, Peosta, USA). Protein concentra-
tions were measured using the Bradford assay (Bio-Rad, CA,
USA) according to manufacturer’s protocol. Proteins were
separated on 10% sodium dodecyl sulfate-polyacrylamide
(SDS-PAGE) gels and transferred to a nitrocellulose mem-
brane. The membrane was blocked with 5% skimmed milk
in TBS-T (10mM Tris-HCl, 150mM NaCl, 0.25% Tween 20,
pH 7.5) at room temperature for 2h followed by incubation
with primary antibody for OCTN2 and GAPDH in TBS
and 5% skimmed milk overnight at 4◦C. After washing,
the membrane was incubated with horseradish peroxidase
(HRP) labeled secondary antibody in TBS-T buﬀer for 2h
at room temperature, followed by three washes with TBS-T.
Thedetectionwasperformedusingchemiluminescenceassay
(Amersham, GE Healthcare, life science, UK). Membranes
were exposed to X-ray ﬁlm to observe the bands (Kodak,
Rochester, NY, USA). Protein bands were quantiﬁed using
the Kodak Scientiﬁc ID software.
2.4.3. Assessment of Serum Creatine Kinase (CK-MB) and
Lactate Dehydrogenase (LDH) Activity. Serum activities of
LDHandCK-MBweredeterminedaccordingtothemethods
of Buhl and Jackson [33]a n dW ua n dB o w e r sJ r[ 34],
respectively.
2.4.4. Determination of Carnitine Levels in Serum, Urine, and
Cardiac Tissues. Carnitine concentrations were determined
in serum, urine, and cardiac tissues according to the method
reported by Prieto et al. [35]. In brief, carnitine reacts with
acetyl-CoA-forming acetylcarnitine in a reaction mediated
by carnitine acetyltransferase enzyme. The liberated CoA-
SH reacts with 5,5-dithiobis-(2-nitrobenzoic acid) forming
thiophenolate ion, whose generation is proportional to the
amount of carnitine and can be measured spectrophoto-
metrically at 412nm. Serum, urine, and heart tissues were
deproteinizedwithequalvolumeofice-cold0.6Mperchloric
acid and allowed to stand in an ice bath for 10min. The
mixture was centrifuged at 1000 ×ga t4 ◦C for 5min. The
supernatant was used directly for measuring free carnitine
after neutralization with 1.2M potassium carbonate. For the
assay of total carnitine, a part of supernatant was mixed
with 1M KOH and incubated at 37◦C for 20min for the
hydrolysis of acylcarnitines. Carnitine level was computed
from a calibration curve for carnitine hydrochloride.
2.5. Statistical Analysis. Diﬀerences between obtained values
(mean ± SEM, n = 10) were carried out by one-way4 Oxidative Medicine and Cellular Longevity
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Figure 1: Eﬀects of cyclophosphamide (CP), ifosfamide (IFO), L carnitine (LC), and their combination on serum cardiotoxicity enzymatic
indices, CK-MB (a) and LDH (b), in rats. Rats were randomly divided into 6 diﬀerent groups of 10 animals each: control, L carnitine, CP,
IFO, CP carnitine supplemented and IFO carnitine supplemented. Carnitine supplementation was induced in rats by daily intraperitoneal
injection of L carnitine (200mg/kg/day) for 10 successive days. CP cardiotoxicity was induced in rats by administration of a single dose
of CP (200mg/kg). IFO cardiotoxicity was induced in rats by administration of IFO (50mg/kg/day, I.P.) for 5 successive days. CP-carnitine
supplementedratsweregiventhesamedosesofLcarnitine(200mg/kg/day)for5daysbeforeand5daysafterasingledoseofCP(200mg/kg).
IFO-carnitine-supplemented rats were given the same doses of L carnitine (200mg/kg/day) for 5 days before and 5 days concomitant with
IFO (50mg/kg/day, I.P.). At the end of the treatment protocol, cardiac enzymes were measured in serum. Data are presented as mean ±
S.E.M. (n = 10). ∗, #,a n d$ indicate signiﬁcant change from control, CP and IFO, respectively, at P<0.05 using ANOVA followed by
Tukey-Kramer as a post-ANOVA test.
analysisofvariance(ANOVA)followedbytheTukey-Kramer
multiple comparison test. P ≤ 0.05 was taken as a criterion
for a statistically signiﬁcant diﬀerence.
3. Results
Figure 1 shows the eﬀects of oxazaphosphorines, L carnitine,
and their combination on cardiotoxicity enzymatic indices,
CK-MB (a) and LDH (b), in rats. Administration of a single
dose of CP (200mg/kg) resulted in a signiﬁcant 77 and
92% increase in serum CK-MB and LDH, respectively, as
compared to the control group. Treatment with L carnitine
(200mg/kg/day) for 10 successive days showed non signiﬁ-
cant changes. Interestingly, administration of L carnitine for
5 days before and 5 days after a single dose of CP resulted
in a complete reversal of CP-induced increase in serum CK-
MB and LDH to the control values. On the other hand,
administration of IFO (50mg/kg/day) for 5 successive days
resulted in 52 and 67% increase in serum CK-MB and LDH,
respectively, as compared to the control group. Carnitine
supplementation by daily administration of L carnitine for
5 days before and 5 days concomitant with IFO resulted in a
complete reversal of IFO-induced increase in serum CK-MB
and LDH to the control values.
To investigate the eﬀects of oxazaphosphorines on
myocardial carnitine transport, the mRNA and protein
expression of OCTN2 was measured in cardiac tissues using
RT-PCR and western blot analysis, respectively (Figure 2).
Treatment with either CP or IFO signiﬁcantly decreased
the expression of OCTN2 on the mRNA (a) and protein
(b) levels in cardiac tissues. A signiﬁcant 50 and 82%
decreaseinmRNAexpressionwasobtainedafterCPandIFO,
respectively, as compared to the control group. Similarly, CP
and IFO signiﬁcantly decreased OCTN2 protein expression
by 54 and 60%, respectively, as compared to the control
group. Daily administration of L carnitine alone for 10
successive days resulted in a signiﬁcant 33% increase in
OCTN2 expression as compared to the control. Interestingly,
administration of L carnitine for 5 days before and 5 days
after a single dose of CP resulted in a complete reversal
of CP-induced decrease in OCTN2 mRNA and protein
expression to the control values. Conversely, administration
of L carnitine to IFO-treated rats did not aﬀect IFO-induced
decrease of OCTN2 expression.
Figure 3 shows the eﬀects of oxazaphosphorines, L
carnitine, and their combination on total carnitine levels in
rat cardiac tissues. Administration of a single dose of CP
and 5 doses of IFO resulted in a signiﬁcant 52 and 41%
decrease in total carnitine level in heart tissues, respectively,
as compared to the control group. On the other hand, daily
administration of L carnitine alone for 10 successive days
resulted in a signiﬁcant 47% increase as compared to the
control rats. Interestingly, administration of L carnitine in
combinationwithCPandIFOresultedinacompletereversal
of the decrease in myocardial carnitine content, induced by
CP and IFO, to the control values.
Figure 4 shows the eﬀects of oxazaphosphorines, L carni-
tine, and their combination on urinary carnitine excretion in
rats. Treatment with a single dose of CP and 5 doses of IFO
resulted in a signiﬁcant 132 and 268% increase in carnitine
excretion, respectively, as compared to the control group.6 Oxidative Medicine and Cellular Longevity
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Figure 2: Eﬀects of cyclophosphamide (CP), ifosfamide (IFO), L carnitine (LC), and their combination on organic cation/carnitine
transporter (OCTN2) mRNA (a) and protein (b) expression in rat heart tissues. Rats were randomly divided into 6 diﬀerent groups of
10 animals each: control, L carnitine, CP, IFO, CP carnitine supplemented and IFO carnitine supplemented. Carnitine supplementation was
induced in rats by daily intraperitoneal injection of L carnitine (200mg/kg/day) for 10 successive days. CP cardiotoxicity was induced in
rats by administration of a single dose of CP (200mg/kg). IFO cardiotoxicity was induced in rats by administration of IFO (50mg/kg/day,
I.P.) for 5 successive days. CP-carnitine-supplemented rats were given the same doses of L carnitine (200mg/kg/day) for 5 days before and 5
days after a single dose of CP (200mg/kg). IFO-carnitine supplemented rats were given the same doses of L carnitine (200mg/kg/day) for 5
days before and 5 days concomitant with IFO (50mg/kg/day, I.P.). At the end of the treatment protocol, total RNA and protein were isolated
from heart tissues, then OCTN2 mRNA and protein expression was measured using RT-PCR and western blot analysis, respectively. Data
are presented as mean ± S.E.M. (n = 10). ∗, #,a n d$ indicate signiﬁcant change from control, CP and IFO, respectively, at P<0.05 using
ANOVA followed by Tukey-Kramer as a post-ANOVA test.
On the other hand, daily administration of L carnitine alone
for 10 successive days resulted in nonsigniﬁcant change in
urinarycarnitineexcretion.Interestingly,administrationofL
carnitineincombinationwithCPandIFOresultedinacom-
plete reversal of the increase in carnitine excretion, induced
by CP and IFO, to the control values. To explain the eﬀects
of oxazaphosphorines on carnitine reabsorption/secretion
rate, the mRNA and protein expression of OCTN2 gene was
measured in kidney tissues using RT-PCR and western blot
analysis, respectively (Figure 5). Administration of either
CP or IFO alone signiﬁcantly decreased the expression of
OCTN2 on the mRNA (a) and protein (b) levels in kidney
tissues. A signiﬁcant 32 and 87% decrease were obtained
after CP and IFO, respectively, as compared to the control
group. Similarly, CP and IFO signiﬁcantly decreased OCTN2
protein expression by 45 and 57%, respectively, as compared
to the control group. Daily administration of L carnitine
alonefor10successivedaysresultedinnonsigniﬁcantchange
in OCTN2 mRNA and protein expression. Interestingly,
administration of L carnitine for 5 days before and 5 days
after a single dose of CP resulted in a complete reversal
of CP-induced decrease in OCTN2 mRNA and protein
expression to the control values. Conversely, administration
of L carnitine to IFO-treated rats did not aﬀect IFO-induced
decrease of OCTN2 expression.
To investigate whether oxazaphosphorines therapy is
associatedwithcarnitineinsuﬃciency,AC/FCratiowasmea-
s u r e di ns e r u mf r o mt r e a t e dr a t s( Figure 6). Administration
of a single dose of CP (200mg/kg) and IFO (50mg/kg/day)
for 5 successive days resulted in a signiﬁcant 183 and 186%
increase in serum AC/FC ratio, respectively, as compared
to the control group. The normal value for AC/FC is less
than 0.4. CP treatment increased AC/FC ratio up to 1.02,
whereas IFO increased AC/FC ratio up to 1.03 indicating
a state of carnitine insuﬃciency. On the other hand, daily
administration of L carnitine alone for 10 successive days
resulted in nonsigniﬁcant change in AC/FC. Interestingly,
administration of L carnitine in combination with CP or
IFO resulted in a complete reversal of the increase in AC/FC,
induced by CP and IFO, to the control values.Oxidative Medicine and Cellular Longevity 7
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Figure 3: Eﬀects of cyclophosphamide (CP), ifosfamide (IFO),
L carnitine (LC), and their combination on the levels of total
carnitine in rat heart tissues. Rats were randomly divided into
6d i ﬀerent groups of 10 animals each: control, L carnitine, CP,
IFO, CP carnitine supplemented and IFO carnitine-supplemented.
Carnitine supplementation was induced in rats by daily intraperi-
toneal injection of L carnitine (200mg/kg/day) for 10 successive
days. CP cardiotoxicity was induced in rats by administration of a
single dose of CP (200mg/kg). IFO cardiotoxicity was induced in
rats by administration of IFO (50mg/kg/day, I.P.) for 5 successive
days. CP-carnitine supplemented rats were given the same doses
of L carnitine (200mg/kg/day) for 5 days before and 5 days after
a single dose of CP (200mg/kg). IFO-carnitine supplemented rats
were given the same doses of L carnitine (200mg/kg/day) for 5 days
before and 5 days concomitant with IFO (50mg/kg/day, I.P.). At the
end of the treatment protocol, total carnitine was measured in heart
tissues. Data are presented as mean ± S.E.M. (n = 10). ∗, #,a n d$
indicate signiﬁcant change from control, CP and IFO, respectively,
at P<0.05 using ANOVA followed by Tukey-Kramer as a post-
ANOVA test.
To investigate the eﬀects of oxazaphosphorines-induced
oxidative stress, the expression levels of GPx and SOD
were measured in heart tissues using RT-PCR (Figure 7).
Administration of either CP or IFO alone signiﬁcantly
decreased the expression of GPx (a) and SOD (b) mRNA
in heart tissues. A signiﬁcant 57 and 50% decrease in GPx
and 60% decrease in SOD were obtained after CP and IFO
treatment, respectively, as compared to the control group.
Daily administration of L carnitine alone for 10 successive
days resulted in nonsigniﬁcant change in the expression of
both genes. However, administration of L carnitine to CP
and IFO-treated rats completely normalized the decrease
in antioxidant enzymes induced by CP and IFO to control
values.
4. Discussion
It is well documented, on the experimental and clinical
levels, that administration of high therapeutic doses of CP
and IFO is associated with cardiotoxicity [3, 4, 7, 9–12, 14–
17]. Although cardiotoxicity is related to dosage, previous
anthracycline and thoracic irradiation-based regimen, age,
and the presence of left ventricular dysfunction, no deﬁnitive
0
1
2
#$ $ $
∗
∗#
C
a
r
n
i
t
i
n
e
e
x
c
r
e
t
i
o
n
(
µ
m
o
l
/
d
a
y
)
CP Control L-carnitine IFO CP + L
carnitine
IFO + L
carnitine
Figure 4: Eﬀects of cyclophosphamide (CP), ifosfamide (IFO),
L carnitine (LC) and their combination on urinary carnitine
excretion in rats. Rats were randomly divided into 6 diﬀerent
groups of 10 animals each: control, L carnitine, CP, IFO, CP
carnitine supplemented, and IFO carnitine supplemented. Carni-
tine supplementation was induced in rats by daily intraperitoneal
injection of L carnitine (200mg/kg/day) for 10 successive days. CP
cardiotoxicity was induced in rats by administration of a single
dose of CP (200mg/kg). IFO cardiotoxicity was induced in rats by
administration of IFO (50mg/kg/day, I.P.) for 5 successive days.
CP-carnitine-supplemented rats were given the same doses of L
carnitine (200mg/kg/day) for 5 days before and 5 days after a
single dose of CP (200mg/kg). IFO-carnitine-supplemented rats
were given the same doses of L carnitine (200mg/kg/day) for 5
days before and 5 days concomitant with IFO (50mg/kg/day, I.P.).
Immediately after the last dose of the treatment protocol, 24 hour-
urinewascollectedformonitoringurinarycarnitineexcretion.Data
are presented as mean ± S.E.M. (n = 10). ∗, #,a n d$ indicate
signiﬁcant change from control, CP and IFO, respectively, at P<
0.05 using ANOVA followed by Tukey-Kramer as a post-ANOVA
test.
risk factors in CP- and IFO-induced cardiotoxicity have
yet been identiﬁed. Recent studies in our laboratory has
demonstrated, for the ﬁrst time, that carnitine deﬁciency
and energy starvation provoke CP and IFO-induced acute
cardiotoxicity and nephropathy in rats [8, 19, 29, 30].
However, up to date in the literature, we could not ﬁnd
any study investigating the molecular mechanism whereby
CP and IFO induce secondary carnitine deﬁciency. Taken
together, this prompted us to investigate, for the ﬁrst time,
whether CP and IFO alter the expression of OCTN2 gene
in cardiac and kidney tissues, and, if so, whether these
alterations contribute to CP and IFO-induced cardiotoxicity.
Under normal physiological conditions, L carnitine is
highly conserved since 95% of the ﬁltered L carnitine
is reabsorbed at the proximal tubular level by speciﬁc
sodium-dependent,highaﬃnityOCTN2[23].Inthecurrent
study, the observed decrease in cardiac carnitine content
following oxazaphosphorines therapy could be due to the
inhibition of endogenous synthesis and/or inhibition of
tubular reabsorption of carnitine. Since kidney is one of
major sites for endogenous carnitine biosynthesis, and 95%
of ﬁltered carnitine is reabsorbed by the proximal tubules
of the nephron [23]; therefore, oxazaphosphorine-induced8 Oxidative Medicine and Cellular Longevity
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Figure 5: Eﬀects of cyclophosphamide (CP), ifosfamide (IFO), L carnitine (LC), and their combination on organic cation/carnitine
transporter (OCTN2) mRNA (a) and protein (b) expression in rat kidney tissues. Rats were randomly divided into 6 diﬀerent groups of
10 animals each: control, L carnitine, CP, IFO, CP carnitine supplemented and IFO carnitine supplemented. Carnitine supplementation was
induced in rats by daily intraperitoneal injection of L carnitine (200mg/kg/day) for 10 successive days. CP cardiotoxicity was induced in
rats by administration of a single dose of CP (200mg/kg). IFO cardiotoxicity was induced in rats by administration of IFO (50mg/kg/day,
I.P.) for 5 successive days. CP-carnitine-supplemented rats were given the same doses of L carnitine (200mg/kg/day) for 5 days before and 5
days after a single dose of CP (200mg/kg). IFO-carnitine-supplemented rats were given the same doses of L carnitine (200mg/kg/day) for 5
days before and 5 days concomitant with IFO (50mg/kg/day, I.P.). At the end of the treatment protocol, total RNA and protein were isolated
from kidney tissues, then OCTN2 mRNA and protein expression was measured using RT-PCR and western blot analysis, respectively. Data
are presented as mean ± S.E.M. (n = 10). ∗, #,a n d$ indicate signiﬁcant change from control, CP and IFO, respectively, at P<0.05 using
ANOVA followed by Tukey-Kramer as a post-ANOVA test.
acute nephropathy may lead to inhibition of endogenous
carnitine biosynthesis and increases its urinary losses with
the consequent secondary deﬁciency of the molecule [29,
30]. This is in line with current data which showed that
urinary carnitine excretion was increased by administration
of CP and IFO. This hypothesis is in line with the only
clinical study performed on 5 patients with advanced soft
tissue sarcoma and reported that IFO-increased urinary
carnitine excretion by factor of 10 [26]. Several studies have
reported that increased urinary excretion of carnitine should
be viewed as an early marker in chemotherapy-induced
nephrotoxicity [36–38].
In the current study, the observed decrease in cardiac
carnitine content by CP and IFO treatment was parallel
to the increase in serum AC/FC and urinary carnitine
excretion, indicating an impaired uptake of carnitine by
cardiac myocytes. The most important carrier in carnitine
uptake is the OCTN2. Physiologically OCTN2 is involved
in the intestinal absorption, myocardial transport, and renal
reabsorption of L carnitine and also plays a major role in
tissue distribution. Variations in transport rates and in levels
of expressed mRNA are also found in diﬀerent tissues [39–
41].Datapresentedhereclearlydemonstratethatoxazaphos-
phorines markedly inhibited OCTN2 mRNA and protein
expression in both heart and kidney tissues. This eﬀect could
be a secondary event following CP- and IFO-induced DNA
double-strand break with the consequent inhibition of RNA
and protein synthesis as a part of its cytotoxic mechanism.
It appears that oxazaphosphorines-induced generation of
free radicals, oxidative and nitrosative stress could be the
cause of decreased OCTN2 mRNA expression [8, 17, 19, 30,
42]. In addition, OCTN2 is directly inhibited by a number
of xenobiotics, including the antibiotic emetine and the
ion channel blockers quintine and verapamil, zwitterionic
compounds such as the b-lactam antibiotics cephaloridine,
cefepime, ceftazidime, and ceﬂuprenam [43, 44].
In the current study, the observed downregulation of
OCTN2 mRNA expression was parallel to the progressive
increase in cardiotoxicity enzymatic indices, LDH and CK-
MB, which may point to the possible contribution of
decreased expression of OCTN2 during development of
oxazaphosphorines-induced cardiotoxicity. In our labora-
tory,decreasedcardiaccarnitinecontentfollowinginhibition
of OCTN2 mRNA expression has been reported in chronic
doxorubicin cardiomyopathic rat model [45]. The possibility
that there is a ﬂux of carnitine from cytosol to extracellular
through OCTN2 or membrane holes produced by CP and
IFO actions cannot be ruled out. Depletion of the heartOxidative Medicine and Cellular Longevity 9
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Figure 6: Eﬀects of cyclophosphamide (CP), ifosfamide (IFO),
L carnitine (LC), and their combination on serum acyl-carnitine
(AC)/free carnitine (FC) ratio in rats. Rats were randomly divided
into 6 diﬀerent groups of 10 animals each: control, L carnitine, CP,
IFO, CP carnitine supplemented, and IFO carnitine supplemented.
Carnitine supplementation was induced in rats by daily intraperi-
toneal injection of L carnitine (200mg/kg/day) for 10 successive
days. CP cardiotoxicity was induced in rats by administration of a
single dose of CP (200mg/kg). IFO cardiotoxicity was induced in
rats by administration of IFO (50mg/kg/day, I.P.) for 5 successive
days. CP-carnitine supplemented rats were given the same doses
of L carnitine (200mg/kg/day) for 5 days before and 5 days after
a single dose of CP (200mg/kg). IFO-carnitine supplemented rats
were given the same doses of L carnitine (200mg/kg/day) for 5 days
before and 5 days concomitant with IFO (50mg/kg/day, I.P.). At the
endofthetreatmentprotocol,serumwasseparated,andAC/FCwas
measured in serum. Data are presented as mean ± S.E.M. (n = 10).
∗, #,a n d$ indicate signiﬁcant change from control, CP and IFO,
respectively, at P<0.05 using ANOVA followed by Tukey-Kramer
as a post-ANOVA test.
fromcarnitinebyoxazaphosphorineswouldimpairthebeta-
oxidation of long-chain fatty acids with the consequent
decrease in ATP production which renders the cardiac
cells vulnerable to damage by oxazaphosphorines with the
consequent leakage of cardiac enzymes. This was supported
by the marked decrease of ATP levels in heart tissues and the
marked increase in cardiacenzymes observed aftertreatment
with both CP and IFO [8, 17, 19, 46].
Under our experimental condition, carnitine supple-
mentation completely restored CP but not IFO-induced
inhibition of OCTN2 mRNA expression in both heart and
kidney tissues to its normal values. Our results are consistent
with the recent in vitro study on human kidney cells which
has demonstrated, for the ﬁrst time, that IFO but not CP
is a substrate for OCTN2, which provide a cell-speciﬁc
explanation for IFO but not CP-induced fanconi syndrome
and oﬀer a new potential target for selective protective
interventions in cancer treatment with oxazaphosphorines
[31]. Authors added that coadministration of cimetidine, a
known competitive substrate of human OCTN2, completely
prevented this IFO-induced toxicity [31]. Therefore, it
seems that IFO produced irreversible inhibition of OCTN2
mRNA expression and that carnitine has nothing to do
with the inhibition of OCTN2 mRNA expression by IFO.
However, it remains unclear why L carnitine normalized
cardiac carnitine content and urinary carnitine excretion in
IFO-treated rats despite irreversible inhibition of OCTN2
expression. A possible explanation for this is that carnitine
supplementation for 10 days will increase the extracellular
concentration of L carnitine that might enter the cells,
under this condition, by simple diﬀusion independent of its
carrier,OCTN2.Moreover,Lcarnitinethroughitspreviously
reported antioxidant defense against generation of reactive
oxygen species (ROS) [47–50] could protect against CP-
induced inhibition of OCTN2 mRNA expression in cardiac
and kidney tissues. Carnitine has a protective eﬀect on
lipid peroxidation by reducing the formation of hydrogen
peroxide [51, 52] and is associated with buﬀering of excess
acyl-CoA, which is potentially toxic to the cells. It also
improved the antioxidant status in rats and showed free
radical scavenging activity as well [53]. In addition, L
carnitine prevents the accumulation of free fatty acids and
their toxic intermediates, thus preventing their harmful
eﬀects on mitochondrial and cell membranes [53]. The
protective eﬀect of L carnitine on kidney and heart tissues
has been proved in some models involving oxidative stress
[54, 55].
It is well documented that L carnitine performs a crucial
role in the energy production in the heart by controlling
the inﬂux of long-chain fatty acids into mitochondria [56].
The total body content of carnitine in adults amounts to 50–
100mmol, most of it being localized in skeletal muscles [26].
CarnitineispresentinbothplasmaandtissueasFCorbound
to fatty acids as AC with relatively high concentration in
cardiac tissues [57]. Under normal physiological conditions,
80% of total serum carnitine is FC, and 20% is AC
with normal AC/FC ratio of 0.25 [58, 59]. Earlier studies
reported that increased ratio of AC/FC greater than 0.4
is abnormal and creates a pathological condition known
as carnitine insuﬃciency in which there is insuﬃcient FC
relative to increased metabolic needs [58–60]. Moreover,
it has been reported that AC/FC ratio is very sensitive to
metabolicchangesandequalstotheintramitochondrialacyl-
CoA/CoA-SH ratio [60].
In this study, oxazaphosphorine therapy increased serum
AC/FC ratio although serum total carnitine is not changed
by CP and IFO as previously reported in our laboratory
[8, 19]. This eﬀect could be a consequence of carnitine
insuﬃciency when esteriﬁed carnitine is exported out of
the mitochondria. Previous study reported that increased
serum AC could indicate impaired transport of long-chain
fatty acids into mitochondria and abnormal beta-oxidation
pathway [58]. Moreover, the observed increase in serum
AC/FC ratio by oxazaphosphorines was parallel to the
increase in cardiotoxicity enzymatic indices, LDH and CK-
MB, which may point to the possible consideration of
serum AC/FC ratio as an index of oxazaphosphorines-
inducedacutecardiotoxicity.ItiswellknownthatLcarnitine
is an essential cofactor for mitochondrial transport and
oxidation of long-chain fatty acids which are the preferred
substrates for ATP production in normal, well-oxygenated
adult myocardium [61].10 Oxidative Medicine and Cellular Longevity
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Figure 7: Eﬀects of cyclophosphamide (CP), ifosfamide (IFO), L carnitine (LC), and their combination on glutathione peroxides (GPx)
(a) and superoxide dismutase (SOD) (b) mRNA expression in rat heart tissues. Rats were randomly divided into 6 diﬀerent groups of 10
animals each: control, L carnitine, CP, IFO, CP carnitine supplemented, and IFO carnitine supplemented. Carnitine supplementation was
induced in rats by daily intraperitoneal injection of L carnitine (200mg/kg/day) for 10 successive days. CP cardiotoxicity was induced in
rats by administration of a single dose of CP (200mg/kg). IFO cardiotoxicity was induced in rats by administration of IFO (50mg/kg/day,
I.P.) for 5 successive days. CP-carnitine-supplemented rats were given the same doses of L carnitine (200mg/kg/day) for 5 days before and 5
days after a single dose of CP (200mg/kg). IFO-carnitine-supplemented rats were given the same doses of L carnitine (200mg/kg/day) for 5
days before and 5 days concomitant with IFO (50mg/kg/day, I.P.). At the end of the treatment protocol, total RNA was isolated from heart
tissues and GPx and SOD mRNA expression was measured using RT-PCR. Data are presented as mean ± S.E.M. (n = 10). ∗, #,a n d$ indicate
signiﬁcant change from control, CP and IFO, respectively, at P<0.05 using ANOVA followed by Tukey-Kramer as a post-ANOVA test.
Damage, at the cellular level by oxidants, is attenuated by
antioxidant enzymes such as SOD, GPx, and catalase [62]. In
the current study, oxazaphosphorines signiﬁcantly decreased
the expression of GPx and SOD in heart tissues. Cardiotoxi-
city secondary to the decrease in antioxidant capacity of the
heartiscausedbyextensiverangeofanticanceragentssuchas
CP and IFO [19, 63]. Increased generation of ROS by CP [7,
64]a n dI F O[ 19] may cause membrane injury by increased
lipid peroxidation associated with decline in the activities
of cellular antioxidants [65]. Superoxide dismutase is one
of the major enzymatic antioxidant mechanisms against
superoxide radical and prevents heart toxicity induced by
oxazaphosphorines [46]. Data presented here showed that
CP and IFO decreasedthe expression of SOD and GPx which
is reversed by carnitine supplementation. The antioxidant
activity of L carnitine and its natural short-chain derivatives
has been previously reported [13, 16, 22, 25]. Our results
are in good agreement with several authors who demon-
strated that oxazaphosphorines induce its cardiotoxicity via
increasing the generation of ROS and decreasing the activity
and expression of antioxidant enzymes in cardiac tissues
[7, 19, 63].
5. Conclusions
Data from this study suggest that (1) oxazaphosphorines
decreased myocardial carnitine content following the inhi-
bition of OCTN2 mRNA and protein expression in cardiac
tissues. (2) Oxazaphosphorines therapy increased urinary
loss of carnitine secondary to the inhibition of OCTN2
mRNA and protein expression in proximal tubules of the
kidney. (3) The progressive increase in cardiotoxicity enzy-
matic indices and the decrease in OCTN2 mRNA expression
may point to the possible contribution of OCTN2 as
a mechanism during development of oxazaphosphorines-
induced cardiotoxicity. (4) Serum AC/FC ratio should be
viewed as an index of oxazaphosphorines-induced acute
cardiotoxicity. (5) Carnitine supplementation attenuates CP
but not IFO-induced inhibition of OCTN2 expression in
heart and kidney tissues. L carnitine is a leading candidate
and should be given along with oxazaphosphorines-based
chemotherapy to block their multiple organ toxicity and to
permitlargerdosesofthesedrugstobeadministered,thereby
killingmorecancercellsandincreasingthechancesofpatient
survival.
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